乾癬性関節炎患者におけるbimekizumabの症状や障害に対する3年間の効果: BE ACTIVE試験結果
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353
Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.